Cytokinetics, Inc. (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, December 6th. The shares were sold at an average price of $7.38, for a total value of $11,070.00. Following the completion of the sale, the executive vice president now directly owns 87,067 shares of the company’s stock, valued at $642,554.46. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Fady Ibraham Malik also recently made the following trade(s):

  • On Thursday, November 1st, Fady Ibraham Malik sold 1,500 shares of Cytokinetics stock. The shares were sold at an average price of $6.68, for a total value of $10,020.00.
  • On Thursday, October 4th, Fady Ibraham Malik sold 1,500 shares of Cytokinetics stock. The shares were sold at an average price of $9.14, for a total value of $13,710.00.

Shares of NASDAQ CYTK traded down $0.17 during midday trading on Friday, hitting $7.40. The company’s stock had a trading volume of 287,489 shares, compared to its average volume of 338,293. The company has a current ratio of 10.57, a quick ratio of 10.58 and a debt-to-equity ratio of 0.73. Cytokinetics, Inc. has a 12-month low of $6.02 and a 12-month high of $10.26.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.11. The business had revenue of $10.64 million during the quarter, compared to analysts’ expectations of $2.23 million. Analysts forecast that Cytokinetics, Inc. will post -1.96 earnings per share for the current year.

Several research firms have recently issued reports on CYTK. HC Wainwright set a $21.00 price objective on Cytokinetics and gave the company a “buy” rating in a research note on Wednesday. Cantor Fitzgerald reiterated a “buy” rating and issued a $14.00 price target on shares of Cytokinetics in a report on Wednesday. BidaskClub upgraded Cytokinetics from a “hold” rating to a “buy” rating in a report on Friday, November 23rd. ValuEngine upgraded Cytokinetics from a “hold” rating to a “buy” rating in a report on Wednesday, November 21st. Finally, Zacks Investment Research upgraded Cytokinetics from a “sell” rating to a “hold” rating and set a $8.00 price target on the stock in a report on Friday, November 2nd. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Cytokinetics currently has an average rating of “Buy” and a consensus price target of $12.83.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Wasatch Advisors Inc. increased its holdings in Cytokinetics by 3.4% during the 3rd quarter. Wasatch Advisors Inc. now owns 1,892,592 shares of the biopharmaceutical company’s stock worth $18,642,000 after purchasing an additional 62,543 shares during the period. Northern Trust Corp increased its holdings in Cytokinetics by 16.7% during the 2nd quarter. Northern Trust Corp now owns 498,546 shares of the biopharmaceutical company’s stock worth $4,138,000 after purchasing an additional 71,418 shares during the period. Millennium Management LLC increased its holdings in Cytokinetics by 351.9% during the 2nd quarter. Millennium Management LLC now owns 461,733 shares of the biopharmaceutical company’s stock worth $3,832,000 after purchasing an additional 359,561 shares during the period. DRW Securities LLC increased its holdings in Cytokinetics by 91.4% during the 2nd quarter. DRW Securities LLC now owns 26,797 shares of the biopharmaceutical company’s stock worth $222,000 after purchasing an additional 12,797 shares during the period. Finally, Rhumbline Advisers increased its holdings in Cytokinetics by 9.0% during the 2nd quarter. Rhumbline Advisers now owns 119,830 shares of the biopharmaceutical company’s stock worth $995,000 after purchasing an additional 9,918 shares during the period. Hedge funds and other institutional investors own 70.47% of the company’s stock.

WARNING: This story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.dailypolitical.com/2018/12/08/cytokinetics-inc-cytk-evp-sells-11070-00-in-stock.html.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.

See Also: Market Capitalization

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.